Downregulation of high mobility group protein box‑1 resensitizes ovarian cancer cells to carboplatin

Shu,Wen

doi:10.3892/ol.2018.9232

Downregulation of high mobility group protein box‑1 resensitizes ovarian cancer cells to carboplatin

Authors:
- Wen Shu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China
Published online on: July 30, 2018 https://doi.org/10.3892/ol.2018.9232
Pages: 4586-4592

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer, one of the most common types of cancer, has the highest mortality among all gynecological malignancies. The development of acquired drug resistance is the leading cause of chemotherapy failure. To study the mechanism underlying drug resistance in ovarian cancer, a drug‑resistant ovarian cancer SKOV3 cell line was developed using the chemotherapeutic agent carboplatin (SKOV3‑Carb) in the present study. It has been reported that high‑mobility group protein box‑1 (HMGB1) is associated with the chemoresistance of tumor cells. Therefore, the probable involvement of HMGB1 in the development of carboplatin resistance in ovarian cancer SKOV3 cells was investigated. HMGB1 has been reported to be overexpressed in carboplatin‑resistant SKOV3‑Carb cells compared with control SKOV3 cells. Subsequently, the expression of HMGB1 was silenced by small interference RNA technology. Reverse transcription‑quantitative polymerase chain reaction and western blot analysis indicated that mRNA and protein expression levels of HMGB1 were significantly inhibited in HMGB1‑silenced cells. Cell proliferation and apoptosis analyses were performed to evaluate the effect of HMGB1 silencing on resistant ovarian cancer cells. An MTT assay revealed that the proliferation of HMGB1‑silenced SKOV3 and SKOV3‑Carb cells were decreased compared with the proliferation of non‑silenced control cells. Additionally, HMGB1 protein expression levels in SKOV3 cells, but not in SKOV3‑Carb cells, were decreased in response to carboplatin treatment. Annexin V‑fluorescein isothiocyanate/propidium iodide staining demonstrated that HMGB1 silencing enhanced the effects of carboplatin in inducing the apoptosis of SKOV3‑Carb cells relative to HMGB1 non‑silenced control cells. The results of the present study suggested that HMGB1 may be involved in the development of carboplatin resistance in ovarian cancer SKOV3 cells and that HMGB1 silencing may induce the sensitization of carboplatin‑resistant ovarian cancer cells to carboplatin. Therefore, HMGB1 may be considered as a potent therapeutic target for increasing the sensitivity of ovarian cancer cells to carboplatin in order to improve the treatment and prognosis of ovarian cancer.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008 v1.2. Cancer incidence, mortality and prevalence worldwideIARC CancerBase No. 10 (Internet). IARC Press; Lyon: 2010
2	Chen WQ, Zhang SW, Zou XN and Zhao P: Cancer incidence and mortality in China, 2006. Chin J Cancer Res. 23:3–9. 2011. View Article : Google Scholar : PubMed/NCBI
3	du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, et al: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd international gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004). Ann Oncol. 16:viii7–viii12. 2005. View Article : Google Scholar : PubMed/NCBI
4	Li R and Linghu H: Treatment progress in epithelial ovarian cancer. J Int Obstet Gynecol. 37:277–280. 2010.(in Chinese).
5	Brouwer-Visser J, Lee J, McCullagh K, Cossio MJ, Wang Y and Huang GS: Insulinlike growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer. PLoS One. 9:e1001652014. View Article : Google Scholar : PubMed/NCBI
6	Wheate NJ, Walker S, Craig GE and Oun R: The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 39:8113–8127. 2010. View Article : Google Scholar : PubMed/NCBI
7	Apps MG, Choi EH and Wheate NJ: The state-of-play and future of platinum drugs. Endocr Relat Cancer. 22:R219–R233. 2015.PubMed/NCBI
8	Wikipedia, the free encyclopedia: Carboplatin. https://en.wikipedia.org/wiki/CarboplatinJune 2–2016
9	Taniguchi N, Yoshida K, Ito T, Tsuda M, Mishima Y, Furumatsu T, Ronfani L, Abeyama K, Kawahara K, Komiya S, et al: Stage-specific secretion of HMGB1 in cartilage regulates endochondral ossification. Mol Cell Biol. 27:5650–5663. 2007. View Article : Google Scholar : PubMed/NCBI
10	Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol. 5:331–342. 2005. View Article : Google Scholar : PubMed/NCBI
11	Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M and Bianchi ME: New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 20:4337–4340. 2001. View Article : Google Scholar : PubMed/NCBI
12	Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta. 1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
13	Bell CW, Jiang W, Reich CF and Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol. 291:C1318–C1325. 2006. View Article : Google Scholar : PubMed/NCBI
14	LeBlanc PM, Doggett TA, Choi J, Hancock MA, Durocher Y, Frank F, Nagar B, Ferguson TA and Saleh M: An immunogenic peptide in the a-box of HMGB1 protein reverses apoptosis-induced tolerance through RAGE receptor. J Biol Chem. 289:7777–7786. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lotze MT and DeMarco RA: Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs. 4:1405–1409. 2003.PubMed/NCBI
16	Park SY, Lee SW, Kim HY, Lee WS, Hong KW and Kim CD: HMGB1 induces angiogenesis in rheumatoid arthritis via HIF-1α activation. Eur J Immunol. 45:1216–1227. 2015. View Article : Google Scholar : PubMed/NCBI
17	Singh A, Feng Y, Mahato N, Li J, Wu C and Gong J: Role of high-mobility group box 1 in patients with acute obstructive suppurative cholangitis-induced sepsis. J Inflamm Res. 8:71–77. 2015. View Article : Google Scholar : PubMed/NCBI
18	Jang A, Liew H, Kim YM, Choi H, Kim S, Lee SH, Ohshima T, Mikoshiba K and Suh YH: p35 deficiency accelerates HMGB-1-mediated neuronal death in the early stages of an Alzheimer's disease mouse model. Curr Alzheimer Res. 10:829–843. 2013. View Article : Google Scholar : PubMed/NCBI
19	Park S, Yoon SJ, Tae HJ and Shim CY: RAGE and cardiovascular disease. Front Biosci (Landmark Ed). 16:486–497. 2011. View Article : Google Scholar : PubMed/NCBI
20	Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C and Bullerdiek J: Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma. 49:1184–1189. 2008. View Article : Google Scholar : PubMed/NCBI
21	Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S and Zornig M: HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 17:1295–1297. 2003. View Article : Google Scholar : PubMed/NCBI
22	Feng A, Tu Z and Yin B: The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer. Oncotarget. 7:20507–20519. 2016. View Article : Google Scholar : PubMed/NCBI
23	Cheng P, Dai W, Wang F, Lu J, Shen M, Chen K, Li J, Zhang Y, Wang C, Yang J, et al: Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE, and AKT pathways. Biochem Biophys Res Commun. 443:1162–1168. 2014. View Article : Google Scholar : PubMed/NCBI
24	Akaike H, Kono K, Sugai H, Takahashi A, Mimura K, Kawaguchi Y and Fujii H: Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res. 27:449–457. 2007.PubMed/NCBI
25	Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, Yoo JS, Paik YK and Kim H: Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest. 89:948–959. 2009. View Article : Google Scholar : PubMed/NCBI
26	Gnanasekar M, Kalyanasundaram R, Zheng G, Chen A, Bosland MC and Kajdacsy-Balla A: HMGB1: A promising therapeutic target for prostate cancer. Prostate Cancer. 2013:1571032013. View Article : Google Scholar : PubMed/NCBI
27	Chen J, Liu X, Zhang J and Zhao Y: Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference. J Cell Physiol. 227:3629–3638. 2012. View Article : Google Scholar : PubMed/NCBI
28	Guo ZS, Liu Z, Bartlett DL, Tang D and Lotze MT: Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res. 3:1–20. 2013.PubMed/NCBI
29	Machado L, Moseley P, Moss R, Nolan C, Rampage J, Chan S and Durrant LG: High-mobility group protein 1 (HMGB1) is an independent predictor of poor survival in ovarian cancerProceedings of the National Cancer Research Institute (NCRI) Cancer Conference. Liverpool, UK: 2014
30	Zhi H, Ma HY and Chen XL: The changes and clinical significance of serum levels of HMGB1, VEGF before and after operation in patients with ovarian carcinoma. Hebei Med J. 36:1297–1299. 2014.(In Chinese).
31	Zhang R, Li Y, Wang Z, Chen L, Dong X and Nie X: Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis. Tumour Biol. 36:8585–8592. 2015. View Article : Google Scholar : PubMed/NCBI
32	Slack JL, Bi W, Livak KJ, Beaubier N, Yu M, Clark M, Kim SH, Gallagher RE and Willman CL: Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction. J Mol Diagn. 3:141–149. 2001. View Article : Google Scholar : PubMed/NCBI
33	Harding M: Ovarian cancer. https://patient.info/doctor/ovarian-cancer-proDecember 2–2016
34	Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
35	Germann UA and Chambers TC: Molecular analysis of the multidrug transporter, P-glycoprotein. Cytotechnology. 27:31–60. 1998. View Article : Google Scholar : PubMed/NCBI
36	Xu Y, Zhi F, Xu G, Tang X, Lu S, Wu J and Hu Y: Overcoming multidrug resistance in vitro and in vivo by a novel P-glycoprotein inhibitor 1416. Biosci Rep. 32:559–566. 2012. View Article : Google Scholar : PubMed/NCBI
37	Sun KK, Ji C, Li X, Zhang L, Deng J, Zhong N and Wu XY: Overexpression of high mobility group protein B1 correlates with the proliferation and metastasis of lung adenocarcinoma cells. Mol Med Rep. 7:1678–1782. 2013. View Article : Google Scholar : PubMed/NCBI
38	Ni P, Zhang Y, Liu Y, Lin X, Su X, Lu H, Shen H, Xu W, Xu H and Su Z: HMGB1 silence could promote MCF-7 cell apoptosis and inhibit invasion and metastasis. Int J Clin Exp Pathol. 8:15940–15946. 2015.PubMed/NCBI
39	Li Z, Wang H, Song B, Sun Y, Xu Z and Han J: Silencing HMGB1 expression by lentivirus-mediated small interfering RNA (siRNA) inhibits the proliferation and invasion of colorectal cancer LoVo cells in vitro and in vivo. Zhonghua Zhong Liu Za Zhi. 37:664–670. 2015.(in Chinese). PubMed/NCBI